Lizorp Suspension 125 mg/5 ml, 250 mg/5 ml Powder for suspension
PDF Leaflet Revision Date: 29 January 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of mild to moderately severe infections caused by susceptible bacteria.
Dosage (summary)
Adults: 500 mg every 24 hours for upper respiratory infections; 250-500 mg every 12 hours for others. Children: 7.5-20 mg/kg depending on infection.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established.
Key Drug Interactions
- Inhibits vitamin K synthesis
- Nephrotoxicity with aminoglycosides
Contraindications
- Hypersensitivity to cephalosporins
- Children under 1 year
- Pregnancy and lactation
Common side effects
- Nausea
- Vomiting
- Diarrhoea
- Dizziness
- Eosinophilia
Counselling Points
- Take with plenty of fluids
- Report any allergic reactions
- Avoid driving if dizzy
Serious warnings
- Serious hypersensitivity reactions
- Pseudomembranous colitis
Important Disclaimer
The Lizorp Suspension 125 mg/5 ml, 250 mg/5 ml Powder for suspension professional information leaflet below is the property of Aurobindo Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
